Alexandra Sanford

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-line nab-paclitaxel days 1, 8, 15 plus carboplatin day 1 of a 21-day cycle (21d) or the same nab-paclitaxel/carboplatin regimen with a 1-week break between cycles (21d + break; 28d). The primary endpoint was the percentage of patients with grade ≥ 2 peripheral neuropathy (PN) or grade ≥ 3 myelosuppression. Other key endpoints included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). A total of 143 patients were randomized (71 to 21d, 72 to 21d + break). The percentage of patients with grade ≥ 2 PN or grade ≥ 3 myelosuppression was similar between the 21d and 21d + break arms (76.5 and 77.1%; P = 0.9258). Treatment exposure was lower in the 21d arm compared with the 21d + break arm. Median OS was 15.2 and 16.2 months [hazard ratio (HR) 0.72, 95% CI 0.44–1.19; P = 0.1966], median PFS was 3.6 and 7.0 months (HR 0.48, 95% CI 0.30–0.76; P < 0.0019), and ORR was 23.9 and 40.3% (risk ratio 1.68, 95% CI 1.02–2.78; P = 0.0376) in the 21d and 21d + break arms, respectively. In summary, the 1-week break between treatment cycles significantly improved PFS and ORR but did not significantly reduce the percentage of grade ≥ 2 PN or grade ≥ 3 myelosuppression. Overall, the findings support the results of prior subset analyses on the safety and efficacy of first-line nab-paclitaxel/carboplatin in elderly patients with advanced NSCLC.

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Introduction The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. Methods Chemotherapy-naive patients with stage IIIB/IV NSCLC and ECOG PS 2 received four cycles of nab-paclitaxel 100 mg/m2 days 1 and 8 plus carboplatin area under the curve 5 day 1 q3w (induction). Patients without progression received nab-paclitaxel monotherapy (100 mg/m2 days 1 and 8 q3w) until progression/unacceptable toxicity. Primary endpoint: percentage of patients discontinuing induction due to treatment-emergent adverse events (TEAEs). Results 11/40 treated patients (27.5%; 95% CI, 14.60–43.89) discontinued chemotherapy induction due to TEAEs; 16/40 (40.0%) continued nab-paclitaxel monotherapy. Median progression-free and overall survival were 4.4 (95% CI, 2.99–7.00) and 7.7 (95% CI, 4.93–13.17) months. Grade 3/4 TEAEs during induction included neutropenia (22.5%), anemia (17.5%), thrombocytopenia (5.0%), and peripheral neuropathy (2.5%). Conclusion This nab-paclitaxel–based regimen was tolerable in patients with advanced NSCLC and ECOG PS 2, with efficacy comparable to historical chemotherapy data.

PS01.08: ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2: Topic: Medical Oncology

Asia (3.1 per 100,000), Northern Africa (2.8 per 100,000), and sub-Saharan Africa (2.2 per 100,000). The lowest estimated mortality rates were for Middle Africa (0.7 per 100,000). Conclusion: With current smoking patterns lung cancer will remain a major cause of death worldwide for several decades. Effective tobacco control policies must be implemented or enforced in order to further reduce smoking prevalence. Lung cancer mortality is likely to greatly increase in sub-Saharan Africa if appropriate tobacco control programs are not implemented. Although smoking is a highly preventable risk factor for lung cancer, exposure to other risk factors.

Poster SessionsPS01.08: ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2: Topic: Medical Oncology

Asia (3.1 per 100,000), Northern Africa (2.8 per 100,000), and sub-Saharan Africa (2.2 per 100,000). The lowest estimated mortality rates were for Middle Africa (0.7 per 100,000). Conclusion: With current smoking patterns lung cancer will remain a major cause of death worldwide for several decades. Effective tobacco control policies must be implemented or enforced in order to further reduce smoking prevalence. Lung cancer mortality is likely to greatly increase in sub-Saharan Africa if appropriate tobacco control programs are not implemented. Although smoking is a highly preventable risk factor for lung cancer, exposure to other risk factors.

PS01.08: ABOUND.PS2 Interim Safety Results: nab -Paclitaxel/Carboplatin Followed by nab -Paclitaxel in NSCLC Patients with ECOG PS of 2

Asia (3.1 per 100,000), Northern Africa (2.8 per 100,000), and sub-Saharan Africa (2.2 per 100,000). The lowest estimated mortality rates were for Middle Africa (0.7 per 100,000). Conclusion: With current smoking patterns lung cancer will remain a major cause of death worldwide for several decades. Effective tobacco control policies must be implemented or enforced in order to further reduce smoking prevalence. Lung cancer mortality is likely to greatly increase in sub-Saharan Africa if appropriate tobacco control programs are not implemented. Although smoking is a highly preventable risk factor for lung cancer, exposure to other risk factors.